Safety and Pharmacokinetics of Multiple Dose of YC-6 in Healthy Subjects

Inclusion Criteria: 1. 18\~55 years old healthy subjects 2. BW ≥ 50 kg, BMI 18\~28 kg/m² 3. Signed the informed consent from to participate voluntarily and to comply with the trial requirements Exclusion Criteria: 1. History of clinically significant cardiovascular, hepatic, renal, gastrointestinal, hematologic diseases 2. Clinically significant abnormality evidenced from detailed physical examination, 12-lead ECG, biochemistry, hematology, and routine urine analysis 3. Glomerular filtration rate (GFR) \< 80 mL/min 4. Any medication within 2 weeks before the first administration in this study 5. History of clinically significant allergy and hypersensitivity 6. Hepatitis B or C, syphilis, or HIV infection on serological examination 7. History of alcoholic addiction or drug abuse within a year before this study 8. Failing of smoking and drunk cessation (Breath carbon monoxide test \> 7 ppm) during this study 9. Participated in any drug trial within 3 months before this study 10. Donated blood or blood product ≥ 400 mL or 2 units within 3 months before this study 11. Dissented to avoid intake of tobacco, alcohol, or caffeine, and strenuous exercise or any behavior that would affect the ADME of YC-6 12. Pregnant or breast-feeding women 13. Other subject conditions unsuitable for enrollment in this study